Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis
Jie Dai , Tianxiao Xu , Lifeng Li , Meiyu Fang , Jing Lin , Jun Cao , Xue Bai , Caili Li , Xiaoting Wei , Junjie Gu , Yaoyao Liu , Xuan Gao , Xuefeng Xia , Jun Guo , Yu Chen , Lili Mao , Lu Si
Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70169
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis
•3-year follow-up study confirmed the therapeutic efficacy of atezolizumab combined with bevacizumab | |
•Tumors in the upper site and NRAS mutations are more sensitive to treatment | |
•Inflammatory cell infiltration, angiogenic status, and activation of the SMAD2 and p38 MAPK pathways may be prognostic indicators |
atezolizumab / bevacizumab / immunotherapy / mucosal melanoma / VEGF inhibitor
2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
